Reverse-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
| Property | Value | Notes |
|---|---|---|
| Dosage form | Lyophilized powder in sealed vial | Reconstituted before analytical or laboratory use |
| Reconstitution solvent | Sterile or bacteriostatic water | Bacteriostatic water limits microbial growth in multi-use vials |
| Typical working pH | Near neutral, buffered | Strongly acidic or basic conditions promote degradation |
| Stability indicator | Loss of main HPLC peak over time | Aggregation and oxidation are common degradation routes |
| Documentation | Batch certificate of analysis | Covers identity, purity and sometimes sterility testing |
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Two-stroke chainsaws require about 2–5% of oil in the fuel to lubricate the engine, while the motor in electrical chain-saws is normally lubricated for life. Most modern gasoline-operated saws today require a fuel mix of 2% (1:50). Gasoline that contains ethanol can result in problems for the equipment because ethanol dissolves plastic, rubber, and other material. This leads to problems, especially on older equipment. A workaround for this problem is to run fresh fuel only and run the saw dry at the end of the work. Separate chain oil or bar oil is used for the lubrication of the bar and chain on all types of chainsaws. The chain oil is depleted because it tends to be thrown off by chain centrifugal force. On two-stroke chainsaws, the chain oil reservoir is usually filled up at the same time as refueling. The reservoir is normally large enough to provide sufficient chain oil between refueling. Lack of chain oil, or using an oil of incorrect viscosity, is a common source of damage to chainsaws, and tends to lead to rapid wear of the bar, or the chain seizing or coming off the bar. In addition to being quite thick, chain oil is particularly sticky (due to "tackifier" additives) to reduce the amount thrown off the chain. Although motor oil is a common emergency substitute, it is lost even faster, leaving the chain less lubricated. Oil is pumped from a small pump to a hole in the bar. From there, the lower ends of each chain drive link take a portion of the oil into the gauge towards the bar nose. The pump outlet and bar hole must be aligned.
The babies from this initial experiment were born in 1954, and the milestone was first publicized in the Cedar Rapids Gazette under the headline "Fatherhood After Death Has Now Been Proved Possible." After receiving his doctorate, Sherman accepted a position at the Biological Research Institute with the American Foundation for Biological Research in Madison, Wisconsin, in 1954. In 1957 Sherman joined the faculty at the University of Arkansas. He served as a professor there until 1992, when he became a professor emeritus and continued work until 1994. At University of Arkansas for Medical Sciences, he founded what is considered to be the second human semen cryobank. During his career, he also traveled by request to assist with the establishment of other cryobanks across the country. He also helped to establish and advocate for the Office of Minority Affairs within the School of Medical Sciences at Arkansas. From 1974 to 1975, he spent a year on sabbatical teaching at National Chung-Hsing University in Taichung, Taiwan. Throughout his career, Sherman was also active in professional societies including his role as a charter member of the Society of Cryobiology in 1964, where he also served on the society's editorial board; as a founder of the American Association of Tissue Banks, where he drafted the first standards for the cryobanking of human embryos; and as an advisor to the Food and Drug Administration on AIDS and cryobanking from 1988 to 1992.
=== Schwann cells and endoneural fibroblasts in PNS === In healthy nerves, nerve growth factor (NGF) is produced in very small amounts. However, upon injury, NGF mRNA expression increases by five to seven-fold within a period of 14 days. Nerve fibroblasts and Schwann cells play an important role in increased expression of NGF mRNA. Macrophages also stimulate Schwann cells and fibroblasts to produce NGF via macrophage-derived interleukin-1. Other neurotrophic molecules produced by Schwann cells and fibroblasts together include brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, ciliary neurotrophic factor, leukemia inhibitory factor, insulin-like growth factor, and fibroblast growth factor. These factors together create a favorable environment for axonal growth and regeneration. Apart from growth factors, Schwann cells also provide structural guidance to further enhance regeneration. During their proliferation phase, Schwann cells begin to form a line of cells called Bands of Bungner within the basal laminar tube. Axons have been observed to regenerate in close association to these cells. Schwann cells upregulate the production of cell surface adhesion molecule ninjurin further promoting growth. These lines of cell guide the axon regeneration in proper direction. The possible source of error that could result from this is possible mismatching of the target cells as discussed earlier. Due to lack of such favorable promoting factors in CNS, regeneration is stunted in CNS.
=== Structure === X-ray structures of DPP-4 that have been published since 2003 give rather detailed information about the structural characteristics of the binding site. Many structurally diverse DPP-4 inhibitors have been discovered and it is not that surprising considering the properties of the binding site: 1. A deep lipophilic pocket combined with several exposed aromatic side chains for achieving high affinity small molecule binding. 2. A significant solvent access that makes it possible to tune the physico-chemical properties of the inhibitors that leads to better pharmacokinetic behavior. DPP-4 is a 766-amino acid transmembrane glycoprotein that belongs to the prolyloligopeptidase family. It consists of three parts; a cytoplasmic tail, a transmembrane region and an extracellular part. The extracellular part is divided into a catalytic domain and an eight-bladed β-propeller domain. The latter contributes to the inhibitor binding site. The catalytic domain shows an α/β-hydrolase fold and contains the catalytic triad Ser630 - Asp708 - His740. The S1-pocket is very hydrophobic and is composed of the side chains: Tyr631, Val656, Trp662, Tyr666 and Val711. Existing X-ray structures show that there is not much difference in size and shape of the pocket that indicates that the S1-pocket has high specificity for proline residues
Guinness Bitter, an English-style bitter beer: 4.4% ABV. Guinness Extra Smooth, a smoother stout sold in Ghana, Cameroon and Nigeria: 5.5% ABV. Malta Guinness, a non-alcoholic beverage, produced in Nigeria and exported to the UK, East Africa, and Malaysia. Guinness Zero ABV, a non-alcoholic beverage sold in Indonesia. Guinness Mid-Strength, a low-alcohol stout test-marketed in Limerick, Ireland in March 2006 and Dublin from May 2007: 2.8% ABV. Guinness Red, brewed in exactly the same way as Guinness except that the barley is only lightly roasted so that it produces a lighter, slightly fruitier red ale; test-marketed in Britain in February 2007: 4% ABV. 250 Anniversary Stout, released in the U.S., Australia and Singapore on 24 April 2009; 5% ABV. Guinness West Indies, a Porter which imitates the 1801 variety with notes of toffee and chocolate: 6% ABV. In October 2005, Guinness announced the Brewhouse Series, a limited-edition collection of draught stouts available for roughly six months each. There were three beers in the series.
Sources: en.wikipedia.org
Half-Life 2: Episode Two is a 2007 first-person shooter game developed and published by Valve. Following Episode One (2006), it is the second of two episodic games that continue the story of Half-Life 2 (2004). The player controls Gordon Freeman, who travels through the mountains surrounding City 17 to a resistance base with his ally Alyx Vance. Like previous Half-Life games, Episode Two combines shooting, puzzle-solving and narrative elements, and adds expansive environments and less linear sequences. Episode Two was released on October 10, 2007, for Windows on Valve's distribution service Steam, and as a part of The Orange Box, a compilation of Valve games for Windows, Xbox 360, and PlayStation 3. The PlayStation version was produced by Electronic Arts. Episode Two received positive reviews. Valve canceled Half-Life 2: Episode Three when they abandoned episodic development and began developing a new game engine. In 2020, after canceling several further Half-Life projects, Valve released Half-Life: Alyx.
=== Earliest work === The study of hydrogen stable isotopes began with the discovery of deuterium by chemist Harold Urey. Even though the neutron was not realized until 1932, Urey began searching for "heavy hydrogen" in 1931. Urey and his colleague George Murphy calculated the redshift of heavy hydrogen from the Balmer series and observed very faint lines on a spectrographic study. To intensify the spectroscopic lines for publishable data, Murphy and Urey paired with Ferdinand Brickwedde and distilled a more concentrated pool of heavy hydrogen, now called deuterium. This work on hydrogen isotopes won Urey the 1934 Nobel Prize in Chemistry.
=== Applications === The biochemical implications of α-KIC are largely connected to other biochemical pathways. Protein Synthesis, skeletal muscle regeneration, and skeletal muscle proteolysis have all been noted to change when ɑ-KIC is taken. There is not much research into the specific mechanisms taking part in these processes, but there is a noticeable correlation between ɑ-KIC ingestion and increased skeletal muscle protein synthesis, regeneration, and proteolysis.
The exact mass of many isotopes was measured leading to the result that hydrogen has a 1% higher mass than expected by the average mass of the other elements. Aston speculated about the subatomic energy and the use of it in 1936. In 1918, Arthur Jeffrey Dempster reported on his mass spectrometer and established the basic theory and design of mass spectrometers that is still used to this day. Dempster's research over his career centered around the mass spectrometer and its applications, leading in 1935 to his discovery of the uranium isotope 235U. This isotope's ability to cause a rapidly expanding fission nuclear chain reaction allowed the development of the atom bomb and nuclear power. In 1932, Kenneth Bainbridge developed a mass spectrometer with a resolving power of 600 and a relative precision of one part in 10,000. He used this instrument to verify the equivalence of mass and energy, E = mc2.
Sources: en.wikipedia.org
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.
It usually reports batch-specific results for purity by chromatography, identity by mass spectrometry, and sometimes peptide content and residual solvents. It applies only to the batch tested, not to a supplier's wider stock.
Purity describes the proportion of the chromatographic signal from the target compound, while peptide content measures how much of the vial's physical mass is peptide. Counter-ions, water and residual acid make up the remainder, so content values are commonly lower.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.